Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Argos tanks as its HIV immunotherapy flunks Phase II

Editor's pick
FierceBiotech
12 January 2015
Pharmaceutical industry

Gilead, Janssen Expand HIV Combo Collaborations

Editor's pick
Genetic Engineering & Biotechnology News
30 December 2014
Pharmaceutical industry

Gilead Sciences, Inc. Can't Do It Alone

Editor's pick
Motley Fool
30 December 2014
New & experimental HIV treatments

European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Editor's pick
Janssen
25 November 2014
New & experimental HIV treatments

HIV Drug Development Pipeline Update, Fall 2014 Edition

Editor's pick
The Body Pro
17 November 2014
New & experimental HIV treatments

Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

Editor's pick
BioPharma Dive
7 November 2014
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

Editor's pick
Gilead press release
7 November 2014
How HIV works

Researchers pinpoint exactly where each building block sits in HIV

Editor's pick
Medical Xpress
4 November 2014
New & experimental HIV treatments

CHMP Announces Positive Opinion for REZOLSTA™, a New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir and Cobicistat

Editor's pick
Janssen press release
1 October 2014
New & experimental HIV treatments

Doctor treats Ebola with HIV drug in Liberia - seemingly successfully

Editor's pick
CNN
27 September 2014
New & experimental HIV treatments

Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved by FDA as Individual HIV Drugs

Editor's pick
The Body
26 September 2014
New & experimental HIV treatments

Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

Editor's pick
Gilead press release
25 September 2014
New & experimental HIV treatments

Gilead's Latest HIV Pill Meets Study Goals

Editor's pick
Wall Street Journal
24 September 2014
New & experimental HIV treatments

Gilead Sciences: A Preview of Important HIV Drug Study Results

Editor's pick
The Street
23 September 2014
New & experimental HIV treatments

PREZCOBIX™ now available for Canadians living with HIV

Editor's pick
Newswire.ca
18 September 2014
New & experimental HIV treatments

First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

Editor's pick
NATAP
16 September 2014
New & experimental HIV treatments

Long acting HIV drugs to be developed

Editor's pick
University of Liverpool press release
15 September 2014
New & experimental HIV treatments

New medicines in development give hope to patients with HIV/AIDS

Editor's pick
Pharmaceutical Research and Manufacturers of America
11 September 2014
New & experimental HIV treatments

New HIV Drug, BMS-986001, Safe and Effective in Treatment-Naive Patients

Editor's pick
The Body
10 September 2014
New & experimental HIV treatments

Drug-level study shows feasibility of long-acting integrase inhibitor cabotegravir

Editor's pick
HIVand hepatitis.com
10 September 2014
Side effects

New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

Editor's pick
HIVandhepatitis.com
9 September 2014
New & experimental HIV treatments

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

Editor's pick
Pharma Letter
4 September 2014
New & experimental HIV treatments

The Role of Triumeq in HIV Treatment

Editor's pick
The Body
4 September 2014
New & experimental HIV treatments

Aiming For HIV's Weak Spot - The new generation of gp120 entry inhibitors

Editor's pick
C&EN - Chemical and Engineering News
2 September 2014